↓ Skip to main content

Cochrane Database of Systematic Reviews

Anti-spasticity agents for multiple sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, October 2003
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Citations

dimensions_citation
223 Dimensions

Readers on

mendeley
197 Mendeley
Title
Anti-spasticity agents for multiple sclerosis
Published in
Cochrane database of systematic reviews, October 2003
DOI 10.1002/14651858.cd001332
Pubmed ID
Authors

David Shakespeare, Mike Boggild, Carolyn A Young

Abstract

Spasticity is a common problem in MS patients causing pain, spasms, loss of function and difficulties in nursing care. A variety of oral and parenteral medications are available. To assess the absolute and comparative efficacy and tolerability of anti-spasticity agents in multiple sclerosis (MS) patients. Randomised controlled trials (RCTs) of anti-spasticity agents were identified using MEDLINE, EMBASE, bibliographies of relevant articles, personal communication, manual searches of relevant journals and information from drug companies. Double-blind, randomised controlled trials (either placebo-controlled or comparative studies) of at least seven days duration. Two independent reviewers extracted data and the findings of the trials were summarised. Missing data were collected by correspondence with principal investigators. A meta-analysis was not performed due to the inadequacy of outcome measures and methodological problems with the studies reviewed. Twenty-three placebo-controlled studies (using baclofen, dantrolene, tizanidine, botulinum toxin, vigabatrin, prazepam and threonine) and thirteen comparative studies met the selection criteria. Only thirteen of these studies used the Ashworth scale, of which only three of the six placebo-controlled trials and none of the seven comparative studies showed a statistically significant difference between test drugs. Spasms, other symptoms and overall impressions were only assessed using unvalidated scores and results of functional assessments were inconclusive. The absolute and comparative efficacy and tolerability of anti-spasticity agents in multiple sclerosis is poorly documented and no recommendations can be made to guide prescribing. The rationale for treating features of the upper motor neurone syndrome must be better understood and sensitive, validated spasticity measures need to be developed.

Mendeley readers

The data shown below were compiled from readership statistics for 197 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 1%
United Kingdom 1 <1%
New Zealand 1 <1%
United States 1 <1%
Unknown 192 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 30 15%
Student > Bachelor 21 11%
Researcher 21 11%
Student > Ph. D. Student 18 9%
Student > Postgraduate 17 9%
Other 44 22%
Unknown 46 23%
Readers by discipline Count As %
Medicine and Dentistry 68 35%
Nursing and Health Professions 16 8%
Agricultural and Biological Sciences 13 7%
Neuroscience 8 4%
Psychology 8 4%
Other 28 14%
Unknown 56 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 411. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2017.
All research outputs
#38,145
of 17,356,510 outputs
Outputs from Cochrane database of systematic reviews
#83
of 11,661 outputs
Outputs of similar age
#545
of 295,582 outputs
Outputs of similar age from Cochrane database of systematic reviews
#3
of 239 outputs
Altmetric has tracked 17,356,510 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,661 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,582 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 239 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.